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bew topics in cardiology have generated as much recent
ebate as the use of biomarkers in primary prevention. It is
idely acknowledged that conventional Framingham risk
actors, such as hyperlipidemia, hypertension, and smoking,
o not identify all patients who will develop cardiovascular
vents. What is uncertain is whether newer tests involving
irculating biomarkers add substantially to our ability to
dentify such patients.
See page 2080
Although biomarkers such as high-sensitivity C-reactive
rotein (CRP) have shown promising associations with
ardiovascular risk, many studies have shown minimal
mprovements in the performance of risk algorithms that
ncorporate CRP or other biomarkers (1,2). This has
timulated interest in combining multiple biomarkers into
arger panels (a “multimarker” approach), under the as-
umption that a group of biomarkers may outperform
ndividual ones. In recent years, this multimarker strategy
as been evaluated in a number of epidemiologic cohort
tudies (2–6). The study by Kim et al. (7) in this issue of the
ournal represents another test of the multimarker approach,
his time using data from a large sample of women enrolled
n the WHI (Women’s Health Initiative) trial. The inves-
igators evaluated the predictive performance of 18 inflam-
atory and hemostatic biomarkers in a nested case-control
tudy involving 321 patients with coronary heart disease and
43 controls. Five biomarkers were significantly associated
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rant from the American Heart Association.ith coronary heart disease after adjustment for conven-
ional risk factors: interleukin-6, D-dimer, factor VII, von
illebrand factor, and homocysteine. CRP achieved only
orderline significance (p  0.08). Incorporation of the 5
iomarkers yielded modest improvements in risk discrimi-
ation, as measured by the area under the receiver-operating
haracteristic curve, or c-statistic (0.73 vs. 0.71 in the
onventional risk factor model, in those free of cardiovas-
ular disease at baseline). There was also moderate improve-
ent in risk classification (net reclassification improvement
NRI]: 6.45%).
Notable strengths of the WHI report include the large
umber of cases, the large panel of biomarkers, and the
arefully performed statistical analyses. Several limita-
ions should be noted, however. First, the case-control
esign does not allow an accurate assessment of model
alibration (e.g., a comparison of predicted and observed
isks). This is because the distribution of predicted risks
n the control group is probably skewed because of the
atching process. Second, although the investigators
rovide estimates of NRI, the validity of such estimates
rom a case-control sample is uncertain, again because of
he potentially skewed risk distribution in the control
ample. Third, several important biomarkers, such as
-type natriuretic peptide (BNP) and urinary albumin
xcretion, were not included in the multimarker set. Last,
t would have been preferable to exclude patients with
revalent cardiovascular disease from all of the analyses.
onventional risk algorithms are designed to be applied
o those without prior cardiovascular disease, in whom
ecisions regarding preventive therapies need to be made.
ortunately, the WHI investigators do report separate
esults from this important subgroup.
Despite these limitations, the study by Kim et al. (7) is
aluable and timely. The basic findings are reassuringly
onsistent with those of prior studies. Indeed, now that a
umber of multimarker studies from large populations have
een published, it is useful to take stock of the answers to
everal core questions in risk prediction.
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May 11, 2010:2092–5 Multiple Biomarkers for Risk Predictionhat Are the Appropriate Statistical Metrics
o Use in Evaluating New Risk Markers?
tudies continue to reinforce the concept that statistically
ignificant associations between biomarkers and outcomes
o not ensure that the biomarkers will be useful for
ndividual risk prediction. An important reason is that
istributions of biomarker values between those who de-
elop and do not develop events overlap substantially, even
hen the group means are significantly different (8). This
oint is highlighted nicely in the figures in the WHI
ubstudy. One consequence is a relatively high proportion of
alse positives and false negatives around any given cut
oint, which reduces the c-statistic. Because the c-statistic
as been criticized as being too stringent a criterion for
redictive models, other metrics have been suggested. The
ewest statistical measures are based on how well a new
arker “reclassifies” patients from one risk category to
nother (9,10). While clinically relevant, reclassification
elies on the existence of well-accepted risk thresholds that
re linked to management decisions.
A general consensus has emerged that studies of new
arkers should report a variety of statistical metrics, includ-
ng both older ones (such as the c-statistic) and newer ones
such as proportion reclassified and NRI) (11). This ap-
roach appears well justified. That said, in most multi-
arker studies, results for the various statistical measures are
ore similar than they are distinct, particularly after differ-
nces in scale are taken into account. For instance, in the
ramingham Heart Study (2,12) and the Malmo Diet and
ancer Study (4), biomarker panels led to minimal im-
rovements across the board in c-statistic, calibration, and
RI. In the present study from the WHI, modest changes
n both the c-statistic and NRI were observed.
hat Are the Best Biomarkers
or Predicting Cardiovascular Risk?
ultimarker studies provide an opportunity for head-to-
ead comparisons of biomarker performance. Surprisingly,
he best-known cardiovascular biomarker, CRP, often fares
orse than other biomarkers in these comparisons. In
everal large multimarker studies, including the present
ne (7), CRP was not a significant predictor of cardio-
ascular events (2,5) or coronary events (4) after adjust-
ent for other biomarkers, such as BNP. Why might
NP, a marker of hemodynamic stress, be a better predictor
f vascular events than CRP? Several possibilities have been
aised, including the presence of elevated ventricular wall
tress secondary to ischemia and/or direct effects of ischemia
n BNP release. Intuitively, the fact that BNP is secreted
lmost exclusively from the heart (providing a “window” on
he myocardium) (13), could explain its higher specificity
ompared with markers such as CRP that come from the
iver or other tissues. chy Do Biomarkers Perform Well
n Some Studies and Not in Others?
lthough most multimarker studies suggest that biomarkers
dd relatively little on top of conventional risk factors, there
re notable exceptions. In the Uppsala Longitudinal Study
f Adult Men, a panel of 4 biomarkers (BNP, cystatin C,
roponin, and CRP) raised the c-statistic from 0.688 to
.748 in those without prior cardiovascular disease, with a
orrespondingly large NRI (26%) (3). In 2 secondary pre-
ention studies, a single biomarker, N-terminal pro-BNP,
ed to sizable increases in the c-statistic (14,15). In contrast,
ost primary prevention studies find only modest increases
n the c-statistic (about 0.01).
These divergent findings are largely attributable to dif-
erences in study populations. The Uppsala cohort was
omposed entirely of elderly men, at the same age, with a
elatively high baseline risk. Conventional risk factors (in-
luding age) predict relatively poorly in such a setting, as
videnced by the baseline c-statistics below 0.70 in the
ppsala study. Conventional risk factors also perform
oorly in secondary prevention populations, as features of
he existing disease are more strongly related to the risk for
ecurrent events than antecedent risk factors. The worse the
rediction with conventional risk factors, the greater the
cope to improve risk prediction metrics with newer markers
e.g., it is easier to increase the c-statistic if the starting
oint is 0.68 rather than 0.75). Thus, biomarkers might be
xpected to perform best in higher risk populations, and the
pidemiologic evidence largely bears this out. This creates a
ilemma, however, as the need for improved risk stratifica-
ion is greatest in low-risk to intermediate-risk patients,
ho as a group are the least likely to be receiving preventive
herapies.
ow Many Biomarkers Does It Take?
f 10 or more biomarkers can fail to improve the accuracy of
isk models (2), how many biomarkers would be considered
ufficient? This question is particularly relevant because
ontemporary technologies could identify scores of new
enetic or circulating biomarkers in coming years (16). Of
ourse, the answer depends on which biomarkers are being
dded, not how many. As shown in the WHI study and
thers, significance in single-marker studies does not ensure
hat a biomarker will enter multimarker risk models. This is
ecause the new biomarkers may provide overlapping infor-
ation. For instance, once a marker such as interleukin-6 or
RP is in a risk model, additional inflammatory markers
ould probably not provide new predictive information. A
ormalization of this concept is described by Pepe and
hompson (17), who performed simulations with 2 hypo-
hetical cancer biomarkers. If the c-statistic is 0.80 with 1
iomarker, the addition of a second predictive biomarker
aises the c-statistic to 0.88 if the 2 biomarkers are weakly
orrelated but only to 0.83 if they are moderately correlated.
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Multiple Biomarkers for Risk Prediction May 11, 2010:2092–5Accordingly, a small number of uncorrelated biomarkers
ill improve risk prediction more than a large number of
orrelated biomarkers. In the Uppsala cohort, the panel that
ignificantly improved discrimination and calibration con-
isted of 4 biomarkers that each represented different
athways (BNP [wall stress], troponin [injury], cystatin C
renal function], and CRP [inflammation]). In general,
iomarkers from the same pathway are much more likely to
e correlated with each other than those coming from
ifferent pathways. The challenge of adding biomarkers
rom different pathways, however, is that one can quickly
un out of pathways known to contribute cardiovascular risk.
he most promising method of finding uncorrelated
iomarkers, in new pathways, may lie in the use of technol-
gies such as proteomics and metabolomics, which are
apable of systemically screening large numbers of molecules
n specimens in an “unbiased” (or less biased) manner.
hat Is the Relevance of
iomarker Studies in the Post-JUPITER Era?
he JUPITER (Justification for the Use of Statins in
revention: An Intervention Trial Evaluating Rosuvastatin)
rial evaluated the effect of rosuvastatin in middle-aged to
lderly patients with CRP 2 mg/dl and baseline low-
ensity lipoprotein 130 mg/dl (18). The risk for cardio-
ascular events was reduced by 44% by treatment with
osuvastatin compared with placebo. If treatment of patients
dentified on the basis of elevated CRP levels can be so
ffective, is it relevant that CRP and other biomarkers have
nly modest predictive utility in observational studies?
It is important to recognize that the JUPITER trial did
ot address the hypothesis that CRP screening was neces-
ary to identify the subjects who benefited from statin
herapy. There was no “control group” for the biomarker
omparison composed of subjects with CRP levels below 2
g/dl. Thus, it is possible that subjects with low CRP levels
2 mg/dl), but otherwise similar risk factor profiles, would
ave derived comparable benefit in terms of relative risk
eduction with rosuvastatin. Indeed, a secondary analysis
xamining the interaction between baseline CRP levels and
reatment outcomes among enrolled participants yielded a
urprising finding. Patients with high CRP levels (above the
edian of 4.2 mg/dl) actually had less benefit from rosu-
astatin than those with lower CRP levels (below the
edian) (p value for interaction  0.015) (19). Further-
ore, there was no evidence of benefit in those who met the
ge and CRP criteria for entry into the trial but had no other
onventional cardiovascular risk factors (19).
Thus, what can one take away from the JUPITER trial
ith respect to the implementation of screening on the basis
f biomarkers? One of the important findings of the
UPITER trial is that the relative risk reduction with
osuvastatin was remarkably consistent across clinical sub-
roups, including those at low to intermediate risk (18).
his finding is consistent with the results of statin trials inigher risk populations (20) and underscores the importance
f absolute risk estimation, because the projected risk
eduction is driven largely by the baseline absolute risk.
hose at very low baseline risk may not derive enough
bsolute benefit (even if the relative risk reduction is
ignificant) to offset the costs and risks of therapy.
Thus, biomarkers (not limited to CRP) that lead to the
efinement of risk estimates might aid treatment decisions.
his still does not imply that routine biomarker screening is
arranted, because existing biomarkers promote relatively
mall movements in predicted absolute risk (4,10). Risk clas-
ification is unlikely to change for most patients. In contrast,
ome patients have a predicted risk near a threshold for
eciding therapy, and in these patients, the additional infor-
ation from a biomarker or multimarker panel may be helpful.
n practice, the treatment thresholds themselves may be low-
red after guideline committees incorporate data from trials
uch as JUPITER. Additional observational studies, perhaps
sing pooled data, would be useful for defining the perfor-
ance of biomarker panels in specific ranges of predicted risk.
Studies such as the one by Kim et al. (7) serve as an
ngoing reminder of the importance of conventional risk
actors in cardiovascular risk assessment. It remains possible
hat some combination of existing biomarkers could serve as
n adjunct to conventional risk assessment, at least in a
ubset of the population. Nonetheless, large improvements
ill likely require the identification of new and more specific
iomarkers of cardiovascular risk.
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